Chemotherapy News and Research

Latest Chemotherapy News and Research

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.

29 Apr 2010

Physicists and oncologists to develop novel ultra sensitive platform for early cancer detection

The SPEDOC project will create the precursor to future devices for individualized diagnosis and monitoring of cancer therapy, which will allow the illness to be treated in earlier stages and at lower doses, reducing or preventing current secondary effects.

29 Apr 2010

Study: Curcumin nanoparticles limit toxicity of cancer therapy

Pre-treatment with curcumin, a component of the spice turmeric, makes ovarian cancer cells more vulnerable to chemotherapy and radiotherapy. Researchers writing in BioMed Central's open access Journal of Ovarian Research found that delivering the curcumin via very small (less than 100nm) nanoparticles enhanced the sensitizing effect.

29 Apr 2010

Study calls for optimized medical treatment for older patients with advanced lung cancer

Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.

29 Apr 2010

Tumor cell factories may be difficult to defeat: Researchers

Many of the colon cancer cells that form tumors can be killed by genetically short-circuiting the cells' ability to absorb a key nutrient, a new study has found. While the findings are encouraging, the test tube study using human colon cancer cells also illustrates the difficulty of defeating these cells, known as cancer stem cells.

29 Apr 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones.

28 Apr 2010

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

DARA BioSciences, Inc. announced today that on April 26, 2010, DARA Therapeutics, a subsidiary of DARA BioSciences, and the Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health (NIH), entered into a Clinical Trials Agreement to advance the clinical study of KRN5500 for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) in patients with cancer. Under the terms of the collaboration, NCI will fund the studies and DARA will supply KRN5500 and placebo.

28 Apr 2010

NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer

Cell Therapeutics, Inc. today announced that the North Central Cancer Treatment Group ("NCCTG") plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast ("mTNBC") cancer, defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2. Additionally, the majority of breast cancers that are associated with the susceptibility mutation (BRCA1) are of the triple-negative type.

28 Apr 2010

Head- and neck-cancer patients who continue to smoke during radiation therapy have poorer overall survival

Smokers who don't quit before radiation therapy for throat, mouth and other head and neck cancers fair significantly worse than those who do, research from the UC Davis Cancer Center has found.

28 Apr 2010

Hana Biosciences announces completion of Marqibo pre-NDA meeting with FDA

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the Company has completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) related to its lead product candidate, Marqibo for the treatment of relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL).

28 Apr 2010

A bitter pill to swallow

Reporting for Kaiser Health News in collaboration with The Washington Post, Sandra Boodman writes: "When Jere Carpentier learned last year that she had advanced colon cancer -- her third malignancy in a dozen years -- she worried about spending hours in a clinic tethered to an intravenous line, enduring punishing chemotherapy that would make her hair fall out.

28 Apr 2010

First Edition: April 27, 2010

Today's headlines focus on the details of health reform that continue to emerge -- including states' reactions to high risk pools and questions about the sweeping expansion of Medicaid.

27 Apr 2010

Study links progression of lethal type of brain tumor with reduced expression of immune system genes

A new study links progression of a lethal type of brain tumor with reduced expression of more than 600 immune system genes, suggesting how complex the immune response is to the cancer and the resulting difficulty in targeting specific immune system proteins for treatment.

27 Apr 2010

Study suggests way to predict tumors most likely to respond to chemotherapy and radiation

Levels of a key type of immune cell are higher in head and neck cancer patients whose tumors are linked to the human papillomavirus, or HPV, according to researchers at the University of Michigan Comprehensive Cancer Center.

27 Apr 2010

ERCC1 Analysis guides patient treatment decisions

Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

26 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

Physicists and oncologists to develop novel ultra sensitive platform for early cancer detection

Study: Curcumin nanoparticles limit toxicity of cancer therapy

Study calls for optimized medical treatment for older patients with advanced lung cancer

Tumor cell factories may be difficult to defeat: Researchers

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer

Head- and neck-cancer patients who continue to smoke during radiation therapy have poorer overall survival

Hana Biosciences announces completion of Marqibo pre-NDA meeting with FDA

A bitter pill to swallow

First Edition: April 27, 2010

Study links progression of lethal type of brain tumor with reduced expression of immune system genes

Study suggests way to predict tumors most likely to respond to chemotherapy and radiation

ERCC1 Analysis guides patient treatment decisions

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

Myths and facts about pediatric cancer

CAT may improve QOL in pediatric oncology patients undergoing therapy: Researchers

Moffitt Cancer Center reports increasing interest in ERCC1 Analysis test for selecting chemotherapy for NSCLC

MicroStockProfit.com releases investment report on ANX

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in